This review looked at different therapeutic strategies that target Tregs, which are a type of immune cell. These strategies included hormonal support, traditional intravenous immunoglobulin, immunometabolic reprogramming, and engineered cellular therapies like chimeric antigen receptor Tregs. The goal was to see if these approaches could help with pregnancy complications such as recurrent implantation failure, recurrent spontaneous abortion, pre-eclampsia, and preterm birth. The study focused on human pregnancy populations.
However, the review did not report specific sample sizes, primary outcomes, or detailed findings for these interventions. There were also no reported details on safety concerns, adverse events, or how well patients tolerated these treatments. Without this specific data, it is difficult to know exactly how effective or safe these strategies are in real-world settings.
Readers should understand that this review highlights potential areas for future research rather than confirming that these treatments work. The lack of reported outcomes means there is currently no clear evidence to support using these therapies routinely. More rigorous studies with clear data on safety and effectiveness are needed before these approaches can be recommended for patients facing these pregnancy challenges.